+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
From
From
From
From
Immunotherapy Drugs Market (2026 Edition) - Product Thumbnail Image

Immunotherapy Drugs Market (2026 Edition)

  • Report
  • January 2026
  • 209 Pages
  • Global
From
From
From
From
Neuroendocrine Tumor Treatment Market in United States - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market in United States

  • Report
  • February 2026
  • 150 Pages
  • United States
From
Neoantigen Targeted Therapy Market in United States - Product Thumbnail Image

Neoantigen Targeted Therapy Market in United States

  • Report
  • December 2025
  • 150 Pages
  • United States
From
From
From
Immuno-Oncology Clinical Trials Market Report 2023-2033 - Product Thumbnail Image

Immuno-Oncology Clinical Trials Market Report 2023-2033

  • Report
  • September 2023
  • 249 Pages
  • Global
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more